The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (Q38153654)

29 August 2017

title

The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (English)

1 reference

29 August 2017

Casey Lythgoe

1

1 reference

29 August 2017

Kevin T McVary

series ordinal

2

1 reference

29 August 2017

publication date

1 December 2013

1 reference

29 August 2017

published in

Current urology reports

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

585-594

1 reference

Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

PDE5 inhibitors for LUTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Chronic ischemia increases prostatic smooth muscle contraction in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Sildenafil influences lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-013-0373-2

Sexual Function and alpha-Blockers

21 January 2018

1 reference

12 December 2020

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study

1 reference

12 December 2020

1 reference

12 December 2020

Inhibition of myofibroblast apoptosis by transforming growth factor beta(1)

1 reference

12 December 2020

Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor

1 reference

12 December 2020

Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide

1 reference

12 December 2020

The impact of lower urinary tract symptoms on male sexual health: EpiLUTS

1 reference

12 December 2020

Chronic ischemia alters prostate structure and reactivity in rabbits

1 reference

12 December 2020

A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia

1 reference

12 December 2020

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia

1 reference

12 December 2020

Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an inte

1 reference

12 December 2020

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

1 reference

12 December 2020

Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit

1 reference

12 December 2020

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

1 reference

12 December 2020

Testosterone Regulates RhoA/Rho-Kinase Signaling in Two Distinct Animal Models of Chemical Diabetes

1 reference

12 December 2020

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

1 reference

12 December 2020

Overactivity and structural changes in the chronically ischemic bladder.

1 reference

12 December 2020

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

1 reference

12 December 2020

Recovery of erectile function after brief aggressive antihypertensive therapy

1 reference

12 December 2020

10.1007/S11934-013-0373-2

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1037400567

0 references

1 reference